Biotech Showcase

As this year’s Nobel Prize winners were walking into Stockholm City Hall for festivities recently, the temperature was climbing below zero in the December night outside.

Journalist and documentary filmmaker Luis Jachmann has visited North Sweden to document Umeå’s role as a life science hub.

BioArctic has entered into a global exclusive license agreement with Bristol Myers Squibb for BioArctic’s PyroGlutamate-amyloid-beta antibody program, including BAN1503 and BAN2803, whereof the latter includes BioArctic’s BrainTransporter technology. 

Novo Nordisk has announced plans to establish a completely new production facility in Odense, Denmark.

Ultimovacs and Zelluna Immunotherapy have announced that Ultimovacs and shareholders of Zelluna representing more than 99% of the total number of issued and outstanding shares in Zelluna have entered into a definitive business combination agreement to combine the two companies in a share exchange transaction.

Hansa Biopharma has announced positive full results from the 15-HMedIdeS-09 single arm Phase 2 study of imlifidase, a first in class IgG cleaving enzyme, in Guillain-Barré Syndrome (GBS) and an indirect treatment comparison of the 15-HMedIdeS-09 study data to the International Guillain-Barré Syndrome Outcome Study (IGOS), a worldwide prospective study by the Inflammatory Neuropathy Consortium on prognosis and biomarkers of GBS.

The PrimaryBid Offering attracted strong interest from both new and existing investors, with participation from over 200 retail investors across Norway, Denmark and Finland.